Please assess the completion status of the following clinical trial:

Trial Title: A Study in Participants With Diabetic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Main Inclusion Criteria:~* Participants with chronic kidney disease presumed due to diabetes Type 1 or Type 2~* Participants with certain levels of kidney function - serum creatinine (SCr) 1.3 to 3.3 mg/dl (115 to 291 micromol/L) inclusive for women and 1.5 to 3.5 mg/dl (132 to 309 micromol/L) inclusive for men, or an estimated glomerular filtration rate (eGFR) 20 to 60 mL/min/1.73 m²~* Participants with protein in the urine - 24-hour urine protein/creatinine ratio (PCR) greater than or equal to 800 mg/g (greater than or equal to 91 mg/mmol).~* Participants must be on a stable and acceptable dose of an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin II receptor blocker), or not able to tolerate these medications.~Main Exclusion Criteria:~* Female participants who can become pregnant, are pregnant or breastfeeding~* Participants who have any of the following medical conditions (the site research staff will discuss these criteria and determine a participant's ability to participate)~  * Chronic inflammatory or autoimmune diseases~ * Chronic Kidney Disease from causes other than diabetes~ * An organ transplant~ * Too high a blood pressure~ * Viral Hepatitis B or C liver infection, liver cirrhosis, or significant liver disease~ * Recent gastrointestinal bleeding~ * Acute kidney injury within the 3 months before screening~ * Major surgery within 3 months before screening or plan to have it during the study period~ * HIV infection- the virus that causes AIDS~ * Heart disease that is not considered stable~ * Cancer that is too recent or other condition which poses too high a risk for developing cancer~ * Required to take drugs that change the immune system

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- 2 mg LY2382770 (Type: EXPERIMENTAL): None
- 10 mg LY2382770 (Type: EXPERIMENTAL): None
- 50 mg LY2382770 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).